Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Dec 4, 2024

(R) Cantargia publishes prospectus in connection with rights issue

Dec 2, 2024

(R) Extraordinary general meeting in Cantargia AB (publ)

Nov 29, 2024

(R) Cantargia expands the CAN10 phase 1 clinical program building on positive results

Nov 15, 2024

(R) Cantargia publishes interim report for third quarter 2024

Nov 13, 2024

(R) Cantargia presents Nomination Committee ahead of 2025 AGM

Nov 11, 2024

Cantargia results showing efficacy of CAN10 in models of myocarditis published in Circulation: Heart Failure

Nov 6, 2024

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

Nov 6, 2024

(R) Cantargia resolves on a rights issue of approximately SEK 170 million

Nov 5, 2024

Cantargia presents promising preclinical results on nadunolimab with antibody-drug conjugates at major immuno-oncology conference

Nov 1, 2024

Invitation to presentation of Cantargia’s interim report January – September 2024

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye